A Gadget For The Heart

HeartWare is developing a family of implantable mechanical circulatory assist devices or "blood pumps", aimed at treating patients with congestive heart failure. Heart failure is one of the leading causes of death in the developed world, affecting over 10 million people globally.

HeartWare's lead product, the HVAD, is the smallest full-output "third generation" circulatory assist device in development. Having completed extensive pre-clinical studies, the HVAD will begin human clinical trials in early 2006. HeartWare's "next generation" device - the MVAD or Miniaturized VAD - is expected to begin clinical trials in approximately two years. The MVAD is one tenth the size of the HVAD. Small size is a key competitive advantage as it facilitates a relatively fast surgical implantation procedure, enhances patient quality of life, and expands the range of patients who might be implanted with the device.

HeartWare listed on the Australian Stock Exchange (ASX: HTW) on 31 January 2005, raising A$32.4 million (US$24.95 million). The Company's Corporate Head Office is in Sydney, Australia and its Operations Centre is in Miami, USA.........